All In Biotech

Drug Trial Radar · NCT06948448

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

Feb 15, 2028

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Conditions

  • Colorectal Cancer

Interventions

  • ONO-4578Drug

    ONO-4578 tablets once a day

  • Opdivo®Drug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • 5-FluorouracilDrug

    Specified dose on specified days

  • BevacizumabDrug

    Specified dose on specified days

  • LeucovorinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)Time frame: From randomization to the end of treatment (Up to 39 months)
  2. Number of participants with Adverse Events (AEs)Time frame: From first dose to 28 days post last dose
  3. Number of participants with Serious Adverse Events (SAEs)Time frame: From first dose to 28 days post last dose

Locations

39 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Advent Health

    Orlando, Florida · Recruiting

  • May Clinic Rochester

    Rochester, Minnesota · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Baylor Scott & White Medical Center

    Temple, Texas · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Blue Ridge Cancer Care

    Salem, Virginia · Recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre- University Health Network

    Toronto, Ontario, Canada · Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, Doubs, France · Recruiting

  • CHU Bordeaux - Hôpital Haut-Lévêque

    Pessac, Gironde, France · Recruiting

  • Chru De Nantes Hotel-Dieu

    Nantes, Loire Atlantique, France · Recruiting

  • Hôpital de la Timone

    Marseille, Marseille, France · Recruiting

  • Hôpital Européen Georges Pompidou

    Paris, Paris, France · Recruiting

  • Hôpital Saint-Antoine

    Paris, Paris, France · Recruiting

  • Centre Leon Berard

    Lyon, Rhone, France · Recruiting

  • CHU Poitiers - Hôpital la Milétrie

    Poitiers, Vienne, France · Recruiting

  • Azienda Socio Sanitaria Territoriale Niguarda

    Milan, Italy, Italy · Recruiting

  • Istituto Clinico Humanitas

    Milan, Italy, Italy · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy, Italy · Recruiting

  • AOU Uni degli Studi Della Campania Lugi Vanvitelli

    Naples, Napoli, Italy · Recruiting

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Napoli, Italy · Recruiting

  • IOV-Istituto Oncologico

    Padova, Padova, Italy · Recruiting

  • Kobe City Medical Center General Hospital

    Hyōgo, Kobe-shi, Japan · Recruiting

  • National Hospital Organization Osaka National Hospital

    Osaka, Osaka-shi, Japan · Recruiting

  • Osaka General Medical Center

    Osaka, Osaka-shi, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Osaka-shi, Japan · Recruiting

  • Institut Catala d'Oncologia (H. Germans Trias I Pujol, ICO-Barcelona)

    Badalona, Barcelona, Spain · Recruiting

  • Hosptial Universitari Vall d'Hebron

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Universitario Reina Sofia

    Córdoba, Córdoba, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, Spain · Recruiting

  • Hospital Regional Universitario de Malaga

    Málaga, Spain, Spain · Recruiting

  • Hospital General Universitario de Valencia

    Valencia, Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.